Vitamin D and vitamin D receptor polymorphism in Asian adolescents with primary dysmenorrhea

BMC Women's Health volume 23, Article number: 414 (2023) Cite this article

Metrics details

The expression of vitamin D receptor in the normal endometrium and ovaries supports the role of vitamin D in local immunity and inflammatory cytokines regulation.

This study aimed to detect the relation between serum 25(OH)D and primary dysmenorrhea in Asian Adolescents.

Two hundred and five (205) adolescents complaining of primary dysmenorrhea (study group) were compared in this prospective study to matched controls (210 controls) after informed consent following the Helsinki Declaration.

After thorough evaluation, including a thorough history and pelvic ultrasound examination, blood samples were collected from the studied adolescents to measure serum 25(OH)D and for vitamin D receptor TaqI (rs731236) genotyping.

The studied adolescents’ data were analyzed using the Pearson’s correlation to detect the relation between serum 25(OH)D and primary dysmenorrhea (primary outcome). The secondary outcome measures the odds of primary dysmenorrhea in Asian adolescents with vitamin D receptor TaqI (rs731236) polymorphism.

The serum 25(OH)D was significantly lower in the studied-dysmenorrhea group compared to controls (16.17 ± 7.36 versus 17.65 ± 6.36 ng/ml, respectively), (P = 0.01). The correlation analysis showed a significant negative correlation between the serum 25(OH)D and visual analogue scale of dysmenorrhea (r = -0.9003, P < 0.0001).

The studied-dysmenorrhea cases with vitamin D receptor T/t and t/t genotypes had significantly lower serum 25(OH)D (16.7 ± 8.05 and 14.4 ± 4.1 ng/ml, respectively) compared to controls (18.97 ± 6.7 and 21.4 ± 2.45 ng/ml, respectively), (P = 0.02 and 0.004, respectively).

The VDR T/t and t/t polymorphisms significantly increase the odds of primary dysmenorrhea (OR 1367.2, P < 0.0001 and OR 106.2, P = 0.001, respectively).

The serum 25(OH)D was significantly lower in the studied-dysmenorrhea group compared to controls. The studied-dysmenorrhea cases with VDR T/t and t/t TaqI genotypes had significantly lower serum 25(OH)D compared to controls. The VDR T/t and t/t polymorphisms significantly increase the odds of primary dysmenorrhea.

Peer Review reports

Primary dysmenorrhea (PD) is painful menstruation without pelvic pathology [1]. The PD starts before the menses and lasts 8–72 h [2].

The PD affects 16–91% of reproductive-age women [3]. A systematic review reported a 71% prevalence of PD in Iran [4]. Dysmenorrhea negatively affects daily activities and work productivity [5].

Increased uterine prostaglandins (PGDs) is the most accepted aetiology of PD [6, 7]. The PGDs increase the amplitude and tone of uterine contractions [7]. Therefore, the non-steroidal anti-inflammatory drugs (NSAIDs) which inhibit the PGDs synthesis are the first-line treatment of PD [8]. The NSAIDs are usually associated with increased risk of gastric ulcers and gastrointestinal bleeding [9, 10]. Therefore, the relief of PD with other therapeutic options could be helpful and limit the use of NSAIDs.

Low serum vitamin D (Vit. D) was reported during the luteal phase of the menstrual cycle [11], and a systematic review reported Vit. D deficiency in severe PD [12].

Agic et al., reported expression of VDR in the normal endometrium and ovaries [13], which supports the role of Vit. D in local immunity and inflammatory cytokines regulation [14].

Vit. D metabolites [i.e., 25(OH)D and 1,25(OH)2D] reduce the levels of inflammatory cytokines and uterine PGDs [15, 16], and the Vit. D supplementation could reduce the severity of PD [17, 18].

The Vit. D receptor (VDR) gene is a protein-coding gene, located on 12q13.11 and expresses a receptor rs731236 that influences the Vit. D binding ability. Any mutation in the VDR gene may result in defective Vit. D binding and subsequent Vit. D deficiency [14].

Considering the anti-inflammatory role of Vit. D and the previous promising results of Vit. D in dysmenorrhea [17, 18], it’s expected that 25(OH)D deficiency and/or VDR TaqI (rs731236) polymorphism could increase the severity of PD.

Therefore, this study was designed based on a hypothesis that 25(OH)D deficiency and/or VDR TaqI (rs731236) polymorphism in Asian adolescents could increase the severity of PD.

Two hundred and five (205) adolescents between 12–18 years-old complaining of PD [study group (dysmenorrhea group)] were compared in this prospective study to matched controls (210 adolescents without dysmenorrhea) of the same age and ethnic characteristics.

Adolescents (study and controls = 415) were recruited for this comparative prospective study, which was conducted from January 2021 to November 2022 (from 43 schools of Aktobe-Kazakhstan) after approval No. 10 dated 04 October 2020 from the ethics committee of West Kazakhstan Medical University (WKMU).

Adolescents were included in this study after informed consent from the adolescents themselves and their parents or legal guardians following the Helsinki Declaration.

The studied adolescents were evaluated thoroughly and examined by an adolescent gynecologist according to the hospital’s protocol.

After a thorough history, the studied adolescents’ weight and height were measured to calculate the body mass index (BMI).

A trans-abdominal pelvic ultrasound was done for the studied adolescents by an expert sonographer blinded to the adolescents’ data using the trans-abdominal convex probe (Samsung HS40, Samsung Co., Korea) to exclude any pelvic pathology.

Inclusion criteria: the study group (205 adolescents) includes adolescents between 12–18 years old, complaining of PD [visual analogue scale (VAS) ≥ 5] for ≥ one year since their menarche, with BMI < 30 kg/m2 and regular menstrual cycle (every 21–35 days). Control group (210 adolescents) includes adolescents between 12–18 years old, without dysmenorrhea for ≥ one year since their menarche, with BMI < 30 kg/m2 and regular menstrual cycle.

Exclusion criteria include adolescents < 12 or > 18 years old, with BMI > 30 kg/m2, pelvic organs anomalies (i.e., including anomalies of the genital and/or urinary tracts) or pelvic pathology (i.e., fibroid uterus and/or ovarian cyst or mass), previous pelvic surgery, neurological or psychiatric disorders or received exogenous hormonal therapy within the last year [19].

The BMI was calculated from the studied adolescents’ body weight and their height (kg/m2) [20, 21].

The WHO considered 18.5–24.9 kg/m2 normal BMI, 25–29.9 kg/m2 overweight, and > 30 kg/m2 obesity class-I [22].

The visual analogue scale (VAS) was used to assess the severity of the studied adolescents’ dysmenorrhea (0 is the lowest VAS and means no pain, while 10 is the highest VAS and means unbearable pain [23].

Blood samples were collected from the studied adolescents to measure the serum 25(OH)D and for VDR TaqI (rs731236) genotyping.

The serum 25(OH)D level was measured using an enzyme-linked immunosorbent assay (Ottignies-Louvain-la-Neuve., Belgium) [14].

Serum 25(OH)D between 20–40 ng/mL was considered normal, while serum 25(OH)D < 20 ng/mL was considered 25(OH)D deficiency according to the endocrine society clinical guideline [24].

The blood samples collected from the studied adolescents were used for DNA extraction using the standard salting out method [14], followed by VDR TaqI genotyping.

The TaqI genotyping was performed using polymerase chain reaction (PCR) and amplification of the targeted region.

Both TaqI wild-type and variant were amplified to produce the same product size (i.e., 148 bp) of the allele-specific primer design [14].

The sequences of the primers covering the targeted gene region were 50-CAGGACGCC GCGCTGATT-30 (forward primer for wild type), 50-CAGGACGCCGCGCTGATC-30 (forward primer sequence for variant allele) and 50-CCTCATTGAGGCTGCGCAG-30 (reverse common primer) [14].

The PCR was optimized after 30 cycles of denaturation at 94°C (5 min.), second denaturation at 94 °C (30 s.), annealing at 60°C (45 s.), and elongation at 72°C (45 s.).

The amplified product was visualized on 2% agarose gel electrophoresis under the Biosystems Genetic Analyzers imaging system (Applied Biosystems and Hitachi, Ltd., US).

The presence of a single 148-bp band either for wild type or variant allele in homozygous condition indicates successful amplification. While the presence of both bands within the same size (148-bp) represent the heterozygous condition [14].

The studied adolescents’ data were analyzed to detect the relation between serum 25(OH)D and PD (primary outcome). The secondary outcome measures the odds of PD in Asian adolescents with VDR TaqI polymorphism.

The required sample size for this study was calculated based on the number of adolescents between 12–18 years-old in Aktobe-Kazakhstan (27,972), prevalence of dysmenorrhea among adolescents (8–83%) and G Power software for sample size calculation (version 3.1.9.7, Düsseldorf; Germany) with 0.05 probability, 0.95% power, 0.5 sample size and student-t test for statistical analysis.

A sample size including ≥ 210 adolescents in two groups (105 in the study group and 105 controls) was enough to produce a statistically acceptable figure.

The SPSS (Statistical Package for Social Sciences) version 25 (Chicago, IL, USA) was used for analysis of the collected adolescents’ data. The mean and standard deviation (± SD) were used to present numerical values. The number (n) and percentage (%) were used to present categorical values.

The student-t test and the Chi-square (x2) were used for analysis of the adolescents’ quantitative and qualitative data, respectively. The correlation analysis was done using the Pearson’s correlation coefficient (r) to detect the relation between serum 25(OH)D and PD. The MedCalc 20.106 (MedCalc. Ltd, Belgium) was also used to calculate the odds ratio (OR) of PD in Asian adolescents with VDR TaqI polymorphism. P < 0.05 considered significant.

The studied-dysmenorrhea group and controls were matched with no significant difference regarding the mean age (14.8 ± 1.7 versus 15.2 ± 1.6 years, respectively), (P = 0.19), height (159.9 ± 3.28 versus 158.4 ± 3.7 cm, respectively), (P = 0.9) and weight (61.8 ± 6.9 versus 60.2 ± 6.4 kg, respectively), (P = 0.1). The studied-dysmenorrhea cases had significantly higher BMI compared to controls (24.2 ± 2.06 versus 23.9 ± 1.65 kg/m2, respectively), (P = 0.0007) Table 1.

The serum 25(OH)D was low in the two-studied groups, and it was significantly lower in the studied-dysmenorrhea group compared to controls (16.17 ± 7.36 versus 17.65 ± 6.36 ng/ml, respectively), (P = 0.01) Table 1 and Fig. 1.

25(OH)D of the studied-dysmenorrhea group compared to controls. PD: Primary dysmenorrhea

The correlation analysis showed a significant negative correlation between the serum 25(OH)D and VAS of dysmenorrhea (r = -0.9003, P < 0.0001) Fig. 2.

Relation between serum 25(OH)D and VAS of dysmenorrhea.VAS: Visual analogue scale

The frequencies of the protective (T) and risky (t) alleles for the studied adolescents were 0.84 (348/425) and 0.16 (67/415), respectively according to the Hardy–Weinberg allele frequencies equation.

According to the protective (T) and risky (t) alleles, the VDR TaqI was divided into T/T (homozygous form), T/t (heterozygous form) and t/t (variant form) genotypes.

The frequencies of the T/T, T/t, and t/t VDR TaqI genotype for the studied adolescents were [0.214 (89/451), 0.624 (259/415) and 0.16 (67/415), respectively].

The frequencies of the T/T, T/t, and t/t VDR TaqI genotype for the studied adolescents (0.214, 0.624 and 0.16, respectively) were statistically similar with no difference when compared to the Hardy–Weinberg genotype frequencies (0.7, 0.27 and 0.03, respectively), (P = 0, 0 and 0, respectively) Fig. 3.

Frequencies of VDR TaqI genotype for the studied adolescents versus the Hardly-Weinberg genotype frequencies. VDR: Vitamin D receptor

The VDR T/t genotype was significantly more frequent in the studied-dysmenorrhea group [76.6% (157/205)] compared to controls [48.6% (102/210)], (P = 0.004).

The VDR T/T genotype was more frequent in the controls [39% (82/210)] compared to the studied-dysmenorrhea group [3.4% (7/205)], (insignificant difference, P = 0), and the VDR t/t genotype was more frequent in the studied-dysmenorrhea group [20% (41/205)] compared to controls [12.4% (26/210)], (insignificant difference, P = 0.07) Table 2.

The studied-dysmenorrhea cases with VDR T/t and t/t genotypes had significantly lower serum 25(OH)D (16.7 ± 8.05 and 14.4 ± 4.1 ng/ml, respectively) compared to controls (18.97 ± 6.7 and 21.4 ± 2.45 ng/ml, respectively), (P = 0.02 and 0.004, respectively) Table 2 and Fig. 4.

The VDR TaqI genotypes and serum 25(OH)D of the two-studied groups. PD: Primary dysmenorrhea. T/t: Heterozygous form. T/T: Homozygous form. t/t: Variant form. VDR: Vitamin D receptor

The studied dysmenorrhea cases with VDR T/T genotype also had lower serum 25(OH)D (13.7 ± 1.6 ng/ml) compared to controls (14.7 ± 5.7 ng/ml), (insignificant difference, P = 1) Table 2 and Fig. 4.

The VDR T/t and t/t polymorphisms significantly increase the odds of PD (OR 1367.2, P < 0.0001 and OR 106.2, P = 0.001, respectively) Table 3.

Increased PGDs is the most accepted aetiology of PD [6, 7]. The PGDs increase the amplitude and tone of uterine contractions [7]. The expression of VDR in the normal endometrium and ovaries [13], supports the role of Vit. D in local immunity and inflammatory cytokines regulation [14].

Vit. D metabolites [i.e., 25(OH)D and 1,25(OH)2D] reduce the inflammatory cytokines [i.e., interleukin-6 (IL-6) and TNF (tumor necrosis factor)] and uterine PGDs [17].

Therefore, two-hundred and five (205) adolescents between 12–18 years-old complaining of PD [study group (dysmenorrhea group)] were compared in this prospective study to matched controls (210 adolescents without dysmenorrhea) to detect the relation between serum 25(OH)D and PD, and the odds of PD in Asian adolescents with VDR TaqI polymorphism.

The serum 25(OH)D was significantly lower in the studied-dysmenorrhea group compared to controls (P = 0.01). The correlation analysis showed a significant negative correlation between the serum 25(OH)D and VAS of dysmenorrhea (r = -0.9003, P < 0.0001).

An observational study found a significant negative correlation between 25(OH)D and dysmenorrhea [16]. The same observational study found the Vit. D intake decreases dysmenorrhea and its associated symptoms [16].

A randomized controlled study reported Vit. D deficiency in dysmenorrhea with a significant negative correlation between the VAS of dysmenorrhea and serum Vit. D [25].

Kucukceran et al., [17] found the VAS of PD and the consumed NSAIDs significantly reduced after a single oral dose of cholecalciferol (300,000 IU) compared to placebo.

Rahnemaei et al., [6] randomized controlled trial reported significant reduction of menstrual pain and consumed analgesics after Vit. D supplementation.

Moreover, Bahrami et al., [26] found the high dose (50,000 IU cholecalciferol/week for 9 weeks) of Vit. D significantly reduces the dysmenorrhea and the premenstrual syndrome.

A systematic review reported a negative association relation between the serum Vit. D/calcium and severity of PD [12].

A recent randomized-controlled trial found the Vit. D supplementation could decrease the severity of PD and the consumed analgesics [27].

The studied-dysmenorrhea cases with VDR T/t and t/t TaqI genotypes had significantly lower serum 25(OH)D compared to controls (P = 0.02 and 0.004, respectively).

The VDR gene is a protein-coding gene, located on 12q13.11 and expresses a receptor rs731236 that influences the Vit. D binding ability. Any mutation in the VDR gene may result in defective Vit. D binding and subsequent Vit. D deficiency and/or defective action [14].

The VDR polymorphism and the subsequent Vit. D deficiency [28, 29] or defective action [30, 31] was reported with different female reproductive disorders [32,33,34].

Pekkinen et al., studied the Vit. D binding protein (DBP) rs4588 gene and reported Vit. D deficiency in adolescents with DBP gene GC polymorphism [28].

Amanzholkyzy et al., studied the VDR polymorphism and found the VDR TaqI t/T polymorphism was associated with significantly lower serum 25(OH)D in Kazakh adolescents [29].

Additionally, a randomized double-blind trial found participants with VDR Taql TT/Tt polymorphisms were more responsive to Vit. D supplementation compared to participants with VDR Taql tt polymorphism [30].

Moreover, Arabi et al., [31] randomized trial found the VDR Taql polymorphism affects the adolescents’ response to Vit. D supplementation.

A literature review (containing retrieved data from 50 scientific sources) reported an association between Vit. D deficiency and different pubertal menstrual dysfunctions [32].

Güleç Yılmaz et al., [33] found the VDR fok1 polymorphism increases the risk for dysmenorrhea, uterine fibroids, and heavy menses. Mun et al., [34] reported an increased risk of ovarian and breast cancers in women with VDR fok1 polymorphism.

Although, the previous studies reported an association between VDR polymorphism and Vit. D deficiency and/or defective action [28,29,30,31]. The current study was the first study conducted in West Kazakhstan to detect the relation between serum 25(OH)D and PD, and the odds of PD in Asian adolescents with VDR TaqI polymorphism.

This study found the serum 25(OH)D was significantly lower in the studied-dysmenorrhea group compared to controls. The correlation analysis showed a significant negative correlation between the serum 25(OH)D and VAS of dysmenorrhea. The studied-dysmenorrhea cases with VDR T/t and t/t TaqI genotypes had significantly lower serum 25(OH)D compared to controls. The VDR T/t and t/t polymorphisms significantly increase the odds of PD.

Although, the BMI of the studied-dysmenorrhea cases was significantly higher compared to controls (P = 0.0007). The relation between BMI and PD is still inconsistent and controversial [35] and needs further research.

Ju et al., [36] reported higher risks of dysmenorrhea in underweight and obese participants. Jiang et al., [37] reported higher odds of dysmenorrhea in women with lower or higher BMI and Gurdip et al., [38] reported a significant relation between dysmenorrhea and underweight or overweight women. The controversial relation between BMI and PD, explains why adolescents with > 30 kg/m2 BMI were excluded from this study.

The limited number of studies investigating the relation between VDR TaqI polymorphism and PD was one of the limitations of this study. The relation between VDR TaqI polymorphism and adolescents’ PD needs to be confirmed in further studies. Adolescents refused to participate was another limitation of this study.

All data generated or analysed during this study were included and submitted for review with the study.

Body mass index

Chi-square

Odds ratio

Interleukin-6

Non-steroidal anti-inflammatory drugs

Polymerase chain reaction

Primary dysmenorrhea

Prostaglandins

Standard deviation

Tumor necrosis factor

Visual analogue scale

Vitamin D receptor

Vitamin D

World Health Organization

West Kazakhstan Medical University

ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent. Obstet Gynecol. 2018;132(6):e249–58. https://doi.org/10.1097/AOG.0000000000002978. [PubMed].

Article Google Scholar

Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. 2015;21(6):762–78. https://doi.org/10.1093/humupd/dmv039.[PubMed].

Article CAS PubMed Google Scholar

Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev. 2014;36:104–13. https://doi.org/10.1093/epirev/mxt009. [PubMed].

Article PubMed Google Scholar

Kharaghani R, Damghanian M. The prevalence of dysmenorrhea in Iran: a systematic review and meta-analysis. Iran Red Crescent Med J. 2017;19: e40856. [Google Scholar].

De Sanctis V, Soliman AT, Elsedfy H, Soliman NA, Soliman R, El Kholy M. Dysmenorrhea in adolescents and young adults: a review in different country. Acta Biomed. 2016;87(3):233–246. [PubMed].

Rahnemaei FA, Gholamrezaei A, Afrakhteh M, Zayeri F, Vafa MR, Rashidi A, et al. Vitamin D supplementation for primary dysmenorrhea: a double-blind, randomized, placebo-controlled trial. Obstet Gynecol Sci. 2021;64(4):353–63. https://doi.org/10.5468/ogs.20316. [PubMed]

Article PubMed PubMed Central Google Scholar

Berek JS. Berek & Novak’s gynecology. 16th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2019. [Google Scholar].

Guimarães I, Póvoa AM. Primary Dysmenorrhea: Assessment and Treatment. Rev Bras Ginecol Obstet. 2020;42(8):501–507. English. doi: https://doi.org/10.1055/s-0040-1712131. [PubMed].

Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs, and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception. 2010;81(3):185–96. https://doi.org/10.1016/j.contraception.2009.09.014. [PubMed].

Article CAS PubMed Google Scholar

Rosales-Alexander JL, Balsalobre Aznar J, Magro-Checa C. Calcium pyrophosphate crystal deposition disease: diagnosis and treatment. Open Access Rheumatol. 2014;6:39–47. https://doi.org/10.2147/OARRR.S39039. [PubMed].

Article CAS PubMed PubMed Central Google Scholar

Abdi F, Ozgoli G, Rahnemaie FS. A systematic review of the role of vitamin D and calcium in premenstrual syndrome. Obstet Gynecol Sci. 2019;62(2):73–86. https://doi.org/10.5468/ogs.2019.62.2.73. [PubMed].

Article PubMed PubMed Central Google Scholar

Abdi F, Amjadi MA, Zaheri F, Rahnemaei FA. Role of vitamin D and calcium in the relief of primary dysmenorrhea: a systematic review. Obstet Gynecol Sci. 2021;64(1):13–26. https://doi.org/10.5468/ogs.20205. [PubMed].

Article PubMed PubMed Central Google Scholar

Agic A, Xu H, Altgassen C, Noack F, Wolfler MM, Diedrich K, et al. Relative expression of 1,25-dihydroxyvitamin D3 receptor, vitamin D 1 alpha-hydroxylase, vitamin D 24-hydroxylase, and vitamin D 25-hydroxylase in endometriosis and gynecologic cancers. Reprod Sci. 2007;14(5):486–97. https://doi.org/10.1177/1933719107304565. [PubMed].

Article CAS PubMed Google Scholar

Kulsoom U, Khan A, Saghir T, Nawab SN, Tabassum A, Fatima S, et al. Vitamin D receptor gene polymorphism TaqI (rs731236) and its association with the susceptibility to coronary artery disease among Pakistani population. J Gene Med. 2021;23(12): e3386. doi: https://doi.org/10.1002/jgm.3386. [PubMed].

Thota C, Laknaur A, Farmer T, Ladson G, Al-Hendy A, Ismail N. Vitamin D regulates contractile profile in human uterine myometrial cells via NF-κB pathway. Am J Obstet Gynecol. 2014;210(4):347.e1-347.e10. https://doi.org/10.1016/j.ajog.2013.11.027. [PubMed].

Article CAS PubMed Google Scholar

Viganò P, Lattuada D, Mangioni S, Ermellino L, Vignali M, Caporizzo E, et al. Cycling and early pregnant endometrium as a site of regulated expression of the vitamin D system. J Mol Endocrinol. 2006;36(3):415–24. https://doi.org/10.1677/jme.1.01946. [PubMed].

Article PubMed Google Scholar

Kucukceran H, Ozdemir O, Kiral S, Berker DS, Kahveci R, Ozkara A, et al. The impact of circulating 25-hydroxyvitamin and oral cholecalciferol treatment on menstrual pain in dysmenorrheic patients. Gynecol Endocrinol. 2019;35(1):53–7. https://doi.org/10.1080/09513590.2018.1490407. [PubMed].

Article CAS PubMed Google Scholar

Lasco A, Catalano A, Benvenga S. Improvement of primary dysmenorrhea caused by a single oral dose of vitamin D: results of a randomized, double-blind, placebo-controlled study. Arch Intern Med. 2012;172(4):366–7. https://doi.org/10.1001/archinternmed.2011.715. [PubMed].

Article PubMed Google Scholar

Vatandost S, Jahani M, Afshari A, Amiri MR, Heidarimoghadam R, Mohammadi Y. Prevalence of vitamin D deficiency in Iran: A systematic review and meta-analysis. Nutr Health. 2018;24(4):269–78. https://doi.org/10.1177/0260106018802968. [PubMed].

Article CAS PubMed Google Scholar

Abdelazim IA, Alanwar A, AbuFaza M, Amer OO, Bekmukhambetov Y, Zhurabekova G, et al. Elevated and diagnostic androgens of polycystic ovary syndrome. Prz Menopauzalny. 2020;19(1):1–5. https://doi.org/10.5114/pm.2020.95293.

Article CAS PubMed PubMed Central Google Scholar

Adilgereyeva AS, Abdelazim IA, Zhurabekova GA, El-Ghazaly TE. Morphological parameters of ovarian masses and accuracy of the risk of malignancy index in diagnosing ovarian malignancy. Prz Menopauzalny. 2022;21(2):81–91. https://doi.org/10.5114/pm.2022.116402.

Article PubMed PubMed Central Google Scholar

Abdelazim IA, Amer OO, Farghali M. Common endocrine disorders associated with the polycystic ovary syndrome. Prz Menopauzalny. 2020;19(4):179–83. https://doi.org/10.5114/pm.2020.101948. [PubMed].

Article CAS PubMed Google Scholar

El-Ghazaly TE, Abdelazim IA, Elshabrawy A. Intrauterine levobupivacaine instillation for pain control in women undergoing diagnostic hysteroscopy. Gynecol Minim Invasive Ther. 2022;11(4):209–14. https://doi.org/10.4103/gmit.gmit_48_21. [PubMed].

Article PubMed PubMed Central Google Scholar

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30. doi: https://doi.org/10.1210/jc.2011-0385. [PubMed].

Karacin O, Mutlu I, Kose M, Celik F, Kanat-Pektas M, Yilmazer M. Serum vitamin D concentrations in young Turkish women with primary dysmenorrhea: A randomized controlled study. Taiwan J Obstet Gynecol. 2018;57(1):58–63. https://doi.org/10.1016/j.tjog.2017.12.009. [PubMed].

Article PubMed Google Scholar

Bahrami A, Avan A, Sadeghnia HR, Esmaeili H, Tayefi M, Ghasemi F, et al. High dose vitamin D supplementation can improve menstrual problems, dysmenorrhea, and premenstrual syndrome in adolescents. Gynecol Endocrinol. 2018;34(8):659–63. https://doi.org/10.1080/09513590.2017.1423466. [PubMed].

Article CAS PubMed Google Scholar

Amzajerdi A, Keshavarz M, Ghorbali E, Pezaro S, Sarvi F. The effect of vitamin D on the severity of dysmenorrhea and menstrual blood loss: a randomized clinical trial. BMC Womens Health. 2023;23(1):138. Published 2023 Mar 27. doi:https://doi.org/10.1186/s12905-023-02284-5. [PubMed].

Pekkinen M, Saarnio E, Viljakainen HT, Kokkonen E, Jakobsen J, Cashman K, et al. Vitamin D binding protein genotype is associated with serum 25-hydroxyvitamin D and PTH concentrations, as well as bone health in children and adolescents in Finland. PLoS One. 2014;9(1): e87292. doi: https://doi.org/10.1371/journal.pone.0087292. [PubMed].

Amanzholkyzy A, Nurgalieva RE, Dosimov AZ, Stankevicius E, Kaldybaeva AT. Ethnic Manifestations of Gene Polymorphisms of Vitamin D Receptor (VDR) in Adolescents of Western Kazakhstan Region. J Natl Med Assoc. 2018;110(1):78–83. https://doi.org/10.1016/j.jnma.2017.02.012. [PubMed].

Article PubMed Google Scholar

Mohseni H, Amani R, Hosseini SA, Ekrami A, Ahmadzadeh A, Latifi SM. Genetic Variations in VDR could Modulate the Efficacy of Vitamin D3 Supplementation on Inflammatory Markers and Total Antioxidant Capacity among Breast Cancer Women: A Randomized Double Blind Controlled Trial. Asian Pac J Cancer Prev. 2019;20(7):2065–72. https://doi.org/10.31557/APJCP.2019.20.7.2065. [PubMed].

Article CAS PubMed PubMed Central Google Scholar

Arabi A, Zahed L, Mahfoud Z, El-Onsi L, Nabulsi M, Maalouf J, et al. Vitamin D receptor gene polymorphisms modulate the skeletal response to vitamin D supplementation in healthy girls. Bone. 2009;45(6):1091–7. https://doi.org/10.1016/j.bone.2009.07.074. [PubMed].

Article CAS PubMed Google Scholar

Bashmakova NV, Lisovskaya TV, Vlasova VY. Pathogenetic role of vitamin D deficiency in the development of menstrual dysfunction in pubertal girls: a literature review. Gynecol Endocrinol. 2017;33(sup1):52–5. https://doi.org/10.1080/09513590.2017.1404235. [PubMed].

Article CAS PubMed Google Scholar

Güleç Yılmaz S, Gül T, Attar R, Yıldırım G, İşbir T. Association between fok1 polymorphism of vitamin D receptor gene with uterine leiomyoma in Turkish populations. J Turk Ger Gynecol Assoc. 2018;19(3):128–31. https://doi.org/10.4274/jtgga.2018.0002. [PubMed].

Article PubMed PubMed Central Google Scholar

Mun MJ, Kim TH, Hwang JY, Jang WC. Vitamin D receptor gene polymorphisms and the risk for female reproductive cancers: A meta-analysis. Maturitas. 2015;81(2):256–65. https://doi.org/10.1016/j.maturitas.2015.03.010. [PubMed].

Article CAS PubMed Google Scholar

Wu L, Zhang J, Tang J, Fang H. The relation between body mass index and primary dysmenorrhea: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2022;101(12):1364–73. https://doi.org/10.1111/aogs.14449. [PubMed].

Article PubMed PubMed Central Google Scholar

Ju H, Jones M, Mishra GD. A U-Shaped Relationship between Body Mass Index and Dysmenorrhea: A Longitudinal Study. PLoS ONE. 2015;10(7): e0134187.

Article PubMed PubMed Central Google Scholar

Jiang W, Hua XG, Hu CY, Li FL, Huang K, Zhang XJ. The prevalence and risk factors of menstrual pain of married women in Anhui Province, China. Eur J Obstet Gynecol Reprod Biol. 2018;229:190–4.

Article PubMed Google Scholar

Gurdip Kaur, Parmjit Kaur, Himani. A Study of the relation of BMI with dysmenorrhea in adolescents’ girls. Int J Curr Res Med Sci 2017; 3(8):65–70. [Google Scholar].

Download references

The authors are grateful to the participants and their parents/guardians for giving consent and participation in this study.

Not applicable.

Department of Normal Physiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

Ainur Donayeva, Ainur Amanzholkyzy, Roza Nurgaliyeva, Samat Saparbayev & Aiman Kaldybayeva

Department of Obstetrics and Gynecology №2, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

Gulnara Gubasheva

Department of Neurology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan

Dinmukhamed Ayaganov

Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Ibrahim A. Abdelazim & Mohamed M. Farghali

You can also search for this author in PubMed Google Scholar

AD designed the study, laboratory assay of 25(OH)D and genotyping, collected the participants’ data, and revised the manuscript before submission. AA designed the study, laboratory assay of 25(OH)D and genotyping, collected the participants’ data, and revised the manuscript before submission. RN explaning and educating the participants and their parents, collected, and analyzed the participants’ data, and revised the manuscript before submission. GG explaning and educating the participants and their parents, collected, and analyzed the participants’ data, and revised the manuscript before submission. SS explaning and educating the participants and their parents, collected, and analyzed the participants’ data, and revised the manuscript before submission. DA explaning and educating the participants and their parents, collected, and analyzed the participants’ data, and revised the manuscript before submission. AK reviewed the literature, updated the references, edited, and statistically analyzed the participants’ data, and revised the manuscript before publication. IAA reviewed the literature, updated the references, edited, and statistically analyzed the participants’ data, and revised the manuscript before publication. MMF reviewed the literature, updated the references, edited, and statistically analyzed the participants’ data, and revised the manuscript before publication. All authors read and approved the final manuscript.

Correspondence to Mohamed M. Farghali.

Participants were included in this study after approval of the institute ethics committee of West Kazakhstan Medical University Meeting No. 10 dated 04.10.2020. Adolescents were included in this study after informed consent was obtained from the adolescents themselves, and their parents or legal guardians following the Helsinki Declaration.

All experiments done in this study were performed in accordance with the Declaration of Helsinki.

Not applicable, identifiable data of participants has not been given in the manuscript.

The authors declare no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

Donayeva, A., Amanzholkyzy, A., Nurgaliyeva, R. et al. Vitamin D and vitamin D receptor polymorphism in Asian adolescents with primary dysmenorrhea. BMC Women's Health 23, 414 (2023). https://doi.org/10.1186/s12905-023-02569-9

Download citation

Received: 20 January 2023

Accepted: 24 July 2023

Published: 05 August 2023

DOI: https://doi.org/10.1186/s12905-023-02569-9

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative